Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Supply Agreement With UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
January 18, 2022
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Accelerating Global Access
December 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
All Hands on Deck Against COVID-19
December 10, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
January 10, 2022
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
January 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
January 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
December 28, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Product Safety
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
December 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
December 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
December 23, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
December 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
December 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
December 17, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
December 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
December 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
December 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Issues $1 Billion Inaugural Sustainability Bond
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Issues $1 Billion Inaugural Sustainability Bond
December 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Bonds
Emissions
Intellectual Property
Exposures
COVID-19
Debt Markets
Intellectual Property
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
December 10, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Merck Prices $8.0 Billion Debt Offering
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
December 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Supports Hiring Our Heroes Corporate Fellowship Program
December 06, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
December 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Fighting for Health Equity From Inside the Health Care Industry
December 03, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
December 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.